iX Biopharma
iX Biopharma raises gross proceeds of S$6.7 million from placement
The amount surpasses the goal of S$5 million; new shares issued at S$0.10 apiece
iX Biopharma proposes placement to raise gross proceeds of at least S$5 million as it eyes US expansion
The placement price represents a discount of 9.7% to the volume weighted average price of S$0.1107 per share
iX Biopharma shares jump 35% on potential US, Australia listing plans
This brings the counter up 408% in the year to date
iX Biopharma H2 loss widens to S$8.3m on fair value adjustments
PHARMACEUTICAL company iX Biopharma posted an S$8.3 million loss for the second half of the fiscal year ended June 2022, sinking deeper into the red from a S$5.4 million loss in H2 FY2021.
iX Biopharma swings into the black in H1 with S$3.7m profit on licensing agreement
CATALIST-LISTED iX Biopharma has swung back into the black with a net profit of S$3.7 million for the first half of its fiscal year ended Dec 31, 2021, compared with a net loss of S$2.8 million the pr...
iX Biopharma hands Seelos exclusive rights for lead drug Wafermine
CATALIST-LISED iX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine, to Seelos Therapeutics - a clinical-stage biopharmaceutical company.
iX Biopharma inks agreement to distribute erectile dysfunction drug in China
PHARMACEUTICAL company iX Biopharma, through its wholly-owned subsidiary, has struck an agreement with China Resources Pharmaceutical Commercial Group Co (CRPCG) for the licensing, supply and distribu...
iX Biopharma inks agreement to distribute erectile dysfunction drug in China
PHARMACEUTICAL company iX Biopharma, through its wholly-owned subsidiary, has struck an agreement with CRPCG for the licensing, supply and distribution of Wafesil, a sublingual sildenafil wafer for th...
iX Biopharma has high hopes for drug spin-off
After the planned HK listing of its pharmaceutical and medical cannabis business, the company will focus on nutraceuticals. BY JANICE HENG
iX Biopharma rights issue closes 196.2% subscribed
IX Biopharma's rights issue closed on July 19 with valid acceptances and valid excess applications amounting to 196.2 per cent of the shares available for subscription, the speciality pharmaceutical c...
